Advanced Prostate Cancer VL

IRONMAN - A Better Understanding of the Variation in Care and Treatment - Daniel George

Details
(Length of Discussion: 17 min) Daniel George, MD and Director of GU Oncology talks with Alicia Morgans, MD about the IRONMAN initiative The project stemmed from the discussion Dr. George had with Dr. Philip Kantoff, MD and Lorelei Mucci, who he worked with on the project, of what is missing in the field of advanced prostate cancer. Dr. George reflects on the number of phase 3 studies that have com...

Navigating the Adverse Effects of ADT - Neal Shore

Details
(Length of lecture - 19 minutes) Dr. Neal Shore addresses both the perception and evidence of side effect for patients on androgen deprivation therapy (ADT). There is a growing concern about ADT side effects now that it is being used more in non-metastatic prostate cancer, which is exposing men to ADT for longer periods of time. Several common adverse effects are known about ADT impacting multiple...

Biomarker Development in Advanced Prostate Cancer- Alicia Morgans

Details
(Length of Discussion: 25 min) Alicia Morgans, MD presents on the topic of biomarker development in advanced prostate cancer. In her presentation, Dr. Morgans discusses the difference between predictive and prognostic biomarkers and the importance of understanding the purpose of each. Also, Dr. Morgans identifies clinical biomarkers for men with mCRPC who are undergoing treatment with docetaxel. L...

Cognitive Function and Hormone Therapy in Advanced Prostate Cancer - Interview with Alicia Morgans

Details
(Length of Conversation: 7 min) Dr. Charles Ryan sits down with Dr. Alicia Morgans to discuss the study she's currently leading on Cognitive Effects of Androgen Receptor (AR) Directed Therapies for Advanced Prostate Cancer . This clinical trial studies cognitive function in men with prostate cancer treated with androgen receptor directed therapies such as abiraterone acetate and enzalutamide. Spec...

Clinical Genomic Risk Classification - Daniel Spratt

Details
A Conversation on Clinical Genomic Risk Classification - Alicia Morgans and Daniel Spratt (Length of Conversation: 25 min) Alicia Morgans, MD talks with Daniel Spratt, MD about the clinical challenges to integrate genomic classifier results that report a continuous numerical risk of recurrence into treatment decisions for prostate cancer (PCa) and how his team aimed to develop a novel clinical-gen...

PRONOUNCE Trial: Cardiovascular Outcomes in Prostate Cancer - Susan Slovin

Details
(Length of Conversation: 19 min) Alicia Morgans, MD, MPH and Susan Slovin, MD, PhD, discuss the PRONOUNCE trial , which looks at cardiovascular outcomes in patients with prostate cancer. Dr. Slovin highlights the importance of considering cardiovascular disease as it is the second most common cause of death in men with prostate cancer. Literature in the past 15-20 years on the use a GNRH agonists...

Role of MRI in Men on Active Surveillance - Laurence Klotz

Details
(Length of Discussion: 33 min) Tom Keane hosts a discussion with Laurence Klotz on the use of MRI in the detection of significant cancer and the possibility of MRI replacing biopsies in men on active surveillance. Dr. Klotz poses the question, can MRI replace biopsies in men on active surveillance? Through an overview of clinical trial data on 12 different published studies around this hot topic i...

Over-treatment in the Name of Cure: Revisiting Adjuvant Therapy in the Modern Era? - Christopher Sweeney

Details
(Length of discussion - 26 minutes) Christopher Sweeney, MD presents on the Over-treatment in the Name of Cure: Revisiting Adjuvant Therapy in the Modern Era? Dr. Sweeney addresses how we can cure more men from prostate cancer by taking a look at preventing relapse after definitive local therapy and radiation and hormonal therapy together vs radiation therapy alone. He reflects on the length of ti...

Navigating the Adverse Effects of ADT: Improving Patient Outcomes - Jehonathan Pinthus and Neal Shore

Details
E. David Crawford hosts a discussion with Neal Shore and Jehonathan Pinthus on the adverse effects of androgen deprivation therapy (ADT). Viewers will gain knowledge on the optimal role of the antagonist vs agonist and a closer look at adverse effects of ADT and recommendations for patients undergoing ADT. The notion of sarcopenia and recommendations in fitness and strength training to reduce risk...

Is the Evidence Sufficient to Recommend Statins for All Men With Prostate Cancer?- Lorelei Mucci

Details
(Length of lecture ~ 19 minutes) Alicia Morgans hosts a discussion with Lorelei Mucci on her recently-published article in the Journal of Clinical Oncology that reviews a study on the association between statin use and the mortality rate in Danish patients who have prostate cancer. This study leverages the unique data sets available in Scandinavian countries where nationwide health registers can b...